A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA<sub>2</sub>R-associated membranous nephropathy.

Although the number of patients with conversion to moderate-to-high risk was close to but did not reach statistical significance, based on the proteinuria reduction and immunomodulatory mechanisms of hydroxychloroquine sulfate, we speculate that this is related to an insufficient sample size.

also in 111,027 other papers